相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
A. Finckh et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine
T. T. MACDONALD et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
Gary R. Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: A Danish single center experience
Ane Sogaard Teisner et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2010)
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease
G. Fiorino et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience
A. Oussalah et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
M. Allez et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
T. R. D. J. Radstake et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Dealing with immunogenicity of biologicals: assessment and clinical relevance
Gerrit J. Wolbink et al.
CURRENT OPINION IN RHEUMATOLOGY (2009)
751f One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
H. Fidder et al.
GUT (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Adalimumab for the treatment of fistulas in patients with Crohn's disease
J-F Colombel et al.
GUT (2009)
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
I. Arijs et al.
GUT (2009)
Endpoints for Clinical Trials Evaluating Disease Modification and Structural Damage in Adults with Crohn's Disease
Geert R. D'Haens et al.
INFLAMMATORY BOWEL DISEASES (2009)
Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
Klaus Bendtzen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Emergence of Crohn's Disease During Treatment with the Anti-Tumor Necrosis Factor Agent Etanercept for Ankylosing Spondylitis: Possible Mechanisms of Action
Boulos Haraoui et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2009)
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
Andrea Rubbert-Roth et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease
R. L. West et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Mark A. Ainsworth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-α antibodies
E. C. Ebert et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
TNFα blockade in human diseases:: Mechanisms and future directions
Maida Wong et al.
CLINICAL IMMUNOLOGY (2008)
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
Arie E. van der Bijl et al.
CLINICAL RHEUMATOLOGY (2008)
494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study
Severine Vermeire et al.
GASTROENTEROLOGY (2008)
T1061 Improvement in Short Inflammatory Bowel Disease Questionnaire Scores in Adalimumab-Treated Crohn's Disease Patients Who Failed Infliximab (CHOICE Trial)
Simon Lichtiger et al.
GASTROENTEROLOGY (2008)
920 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease After Infliximab Failure: 1-Year Follow-Up of Gain Trial
Remo Panaccione et al.
GASTROENTEROLOGY (2008)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Murat Toruner et al.
GASTROENTEROLOGY (2008)
Hepatosplenic T cell lymphoma in inflammatory bowel disease
Matthew Shale et al.
GUT (2008)
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use
Silvio Danese et al.
INFLAMMATORY BOWEL DISEASES (2008)
The use of adalimumab in the management of refractory Crohn's disease
G. -T. Ho et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies
M. Svenson et al.
RHEUMATOLOGY (2007)
Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis
G. G. Kaplan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
The genetics of inflammatory bowel disease
Judy H. Cho et al.
GASTROENTEROLOGY (2007)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Unravelling the pathogenesis of inflammatory bowel disease
R. J. Xavier et al.
NATURE (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006
M. Clark et al.
GASTROENTEROLOGY (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Gastroenterology 1 - Inflammatory bowel disease: cause and immunobiology
Daniel C. Baumgart et al.
LANCET (2007)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents
Axel Finckh et al.
ARTHRITIS AND RHEUMATISM (2007)
Adalimumab in patients with Crohn's disease -: safety and efficacy in an open-label single centre study
J. Seiderer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Review article: the burden of hepatic encephalopathy
F. F. Poordad
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
Ann Corken Mackey et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
Klaus Bendtzen et al.
ARTHRITIS AND RHEUMATISM (2006)
Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study
Edouard I. Louis et al.
PHARMACOGENETICS AND GENOMICS (2006)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
GR Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
TA Yousry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
New concepts in the pathophysiology of inflammatory bowel disease
G Bamias et al.
ANNALS OF INTERNAL MEDICINE (2005)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease
T Hlavaty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2005)
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis
GJ Wolbink et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial
EC Keystone et al.
ARTHRITIS AND RHEUMATISM (2004)
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
E Louis et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease
WJ Sandborn et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Response to infliximab is related to disease duration in paediatric Crohn's disease
P Lionetti et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
MH Weisman et al.
CLINICAL THERAPEUTICS (2003)
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
RJ Farrell et al.
GASTROENTEROLOGY (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Natalizumab for active Crohn's disease.
S Ghosh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Infliximab improves quality of life in patients with Crohn's disease
GR Lichtenstein et al.
INFLAMMATORY BOWEL DISEASES (2002)
Long-term evolution of disease behavior of Crohn's disease
J Cosnes et al.
INFLAMMATORY BOWEL DISEASES (2002)
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
WJ Sandborn et al.
GASTROENTEROLOGY (2001)
Infliximab and methotrexate in the treatment of rheumatoid arthritis
PE Lipsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)